Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab. (10th August 2021) - Brunner, P.M.; Conrad, C.; Vender, R.; Grond, S.; Schuster, C.; Patel, H.; Xu, W.; Carrascosa Carrillo, J.M.